Implementing Effective Early Phase Trial Strategies in Asia to Reduce Approval Timelines, Risks and Costs from First-In-Human through Proof of Concept

In March 2012, the number of clinical trials registered in Asia reached almost 19,922. Also, we have seen a significant increase in the number of early-phase clinical trials conducted in Asia with more and more multinational pharmaceutical and biopharmaceutical companies planning early phase clinical trials including First-in-Human trials in the next 2 years.

What strategies are you putting in place to reduce timelines and prevent early and late phase failures?

The 2nd Annual Early Phase Clinical Trials Asia 2012 summit is returning this August as a high-level platform to gather Heads of Clinical Development/Research, Medical Directors, Principle Investigators, Heads of R & D from pharmaceutical, biopharmaceutical companies and CROs from Mainland China, India, Taiwan, Korea, Hong Kong and other Southeast Asian countries. They will discuss the most efficient way to overcome regulatory, scientific and operational challenges in developing early phase clinical trials in Asian markets.

• Download the brochure to find out more
• Find out who’s attending Early Phase Clinical Trials Asia

Attend Early Phase Clinical Trials Asia 2012 and:

• Learn effective approaches to overcome regulatory challenges for early phase trial approval in China, India and Korea
• Improve your translational strategy: Align preclinical models with optimised clinical strategies
• Design a streamlined safety early phase study to mitigate risks and costs
• Outsource strategies and partnership selection and maintenance with CROs
• Utilise effective modelling and simulation tools – Examine how this has been successfully used

» Register now

Media Partners